Idex Corporation (NYSE:IEX) is renowned for its production of engineered products, including the Jaws of Life device. On October 29, 2025, IEX reported its earnings before the market opened. The company achieved an earnings per share (EPS) of $1.69, which fell short of the estimated $1.93. However, IEX's revenue was $878.7 million, surpassing the estimated $861.4 million.
In the third quarter of 2025, IEX reported a revenue of $878.7 million, marking a 10.1% increase compared to the same period last year. This revenue figure exceeded the Zacks Consensus Estimate of $858.37 million, resulting in a positive surprise of 2.37%. The company's ability to surpass revenue expectations highlights its strong financial performance and effective execution across various business units.
IEX's financial metrics provide further insight into its performance. The company has a price-to-earnings (P/E) ratio of approximately 27.45, indicating investor confidence in its earnings potential. The price-to-sales ratio stands at about 3.83, reflecting the value placed on each dollar of sales. Additionally, IEX maintains a strong liquidity position with a current ratio of 2.93, suggesting it can comfortably cover its short-term liabilities.
The company's debt-to-equity ratio is extremely low at 0.00017, indicating minimal reliance on debt for financing. This financial stability, combined with an earnings yield of 3.64%, provides insight into the return on investment for shareholders. IEX's enterprise value to sales ratio is around 3.66, and its enterprise value to operating cash flow ratio is approximately 19.44, highlighting the company's valuation in relation to its sales and cash flow from operations.
